NPF gives Ilumya its Seal of Recognition for usability and safety

The National Psoriasis Foundation awarded Sun Pharma’s Ilumya the Seal of Recognition, calling it the first systemic prescription medication to receive the honor. The decision highlights a treatment option that avoids self-injection, a practical barrier for many adults living with plaque psoriasis.

Why it matters: - The National Psoriasis Foundation Seal of Recognition signals products that can reduce barriers for people living with psoriasis. - Ilumya’s award matters because the therapy is administered by a healthcare professional, which can ease treatment for patients who struggle with self-injection. - The recognition also spotlights safety and usability as part of the treatment experience, not just clinical efficacy.

What happened: - The National Psoriasis Foundation said Sun Pharma’s Ilumya earned the NPF Seal of Recognition for ease of usability and safety. - The foundation said Ilumya is the first systemic prescription medication to receive the Seal. - The announcement was made Aug. 6, 2026, in Alexandria, Virginia.

The details: - Ilumya is administered in a clinical setting by a healthcare professional. - The dosing model removes the need for patients to prepare or self-inject medication. - The foundation said self-injection can be a significant physical challenge for many people living with psoriasis and can add to treatment burden. - Products earn the Seal by submitting independent lab data to a panel of experts that reviews safety. - The foundation said Seal recipients show a commitment to creating safe products for more than 8 million people in the U.S. and 125 million people worldwide affected by psoriasis. - Ilumya (tildrakizumab-asmn) is indicated by the U.S. Food and Drug Administration for adults with moderate-to-severe plaque psoriasis who are candidates for systemic treatments or phototherapy. - The NPF Seal of Recognition also covers products intended to be non-irritating and safe for people living with psoriasis or psoriatic arthritis. - The Seal directory also includes products safe for daily skincare routines for sensitive skin or suitable for people with joint mobility limitations.

Between the lines: - The award favors treatments that reduce practical friction for patients, especially those who may have trouble with injections. - NPF’s criteria suggest the organization is broadening the conversation about psoriasis care beyond drug performance to include day-to-day usability. - The recognition may help position healthcare professional-administered therapies as a patient-friendly alternative in a market where self-injection is common.

What's next: - Sun Pharma can now reference the NPF Seal of Recognition in connection with Ilumya’s usability and safety profile. - NPF will continue using its Seal program to highlight products that meet its standards for people living with psoriasis and psoriatic arthritis. - The award may draw more attention to treatment formats that reduce self-administration barriers for adults with plaque psoriasis.

The bottom line: - Ilumya’s Seal of Recognition underscores a simple message: easier administration can be a meaningful part of psoriasis care.